Meta-Targeting

Key Info

Basic Information

Coordinator:
Portrait: Prof. Dr. Twan Lammers © Copyright: Stefan Hense
Prof. Dr. Twan Lammers
Faculty:
Medicine
Organizational Unit:
Institute of Experimental Molecular Imaging
Pillar:
Excellent Science
Project duration:
01.04.2020 to 31.03.2025
EU contribution:
1.979.375 euros
  EU flag and ERC logo This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 864121)  

Title

Macro-Nanomedicine to Treat Metastatic Cancer

Concept

The ultimate goal of the EU-funded Meta-Targeting project is to develop a novel, complex, nanomedicine-based approach that will improve the efficacy and decrease the side effects of treatment of metastatic breast cancer. The project's objective is to introduce multifunctional polymeric micelles co-loaded with three different drugs and with an imaging agent. In addition to the anti-tumour drug doxorubicin, the co-loading with the angiotensin receptor inhibitor losartan will help to improve the delivery of micelles. The co-loading with the P-glycoprotein inhibitor tariquidar will improve anti-tumour efficacy without typical side effects such as neurotoxicity. The imaging- and biopsy-based biomarkers are necessary for patient stratification, which is important for the clinical translation of cancer nanomedicines.

Additional information

This grant is hosted at the University Hospital RWTH Aachen (UKA).